FDA Calls Out Manufacturer for Maintenance, Quality Control

Drug GMP Report
A A
The FDA hit Pennsylvania drugmaker Bio-Pharm with a Form 483 after an agency inspection in January revealed poor equipment maintenance and quality control issues.

To View This Article:

Login

Subscribe To Drug GMP Report